Barrow, Hanley, Mewhinney & Strauss
TEVA icon

Barrow, Hanley, Mewhinney & Strauss’s Teva Pharmaceuticals TEVA Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,942,539
Closed -$46.1M – 359
2019
Q1 		$46.1M Buy
2,942,539
+112,888
+4% +$1.99M 0.08% 131
2018
Q4 		$43.6M Sell
2,829,651
-49,183
-2% -$1.01M 0.09% 129
2018
Q3 		$62M Buy
2,878,834
+47,700
+2% +$1.11M 0.1% 130
2018
Q2 		$68.9M Sell
2,831,134
-6,700
-0.2% -$137K 0.11% 124
2018
Q1 		$48.5M Sell
2,837,834
-40,659
-1% -$794K 0.08% 138
2017
Q4 		$54.5M Sell
2,878,493
-1,838,375
-39% -$27.7M 0.08% 135
2017
Q3 		$83M Sell
4,716,868
-25,246,962
-84% -$568M 0.13% 109
2017
Q2 		$995M Buy
29,963,830
+209,848
+0.7% +$6.5M 1.51% 28
2017
Q1 		$955M Sell
29,753,982
-2,701,450
-8% -$92.2M 1.44% 29
2016
Q4 		$1.18B Buy
32,455,432
+5,884,444
+22% +$235M 1.76% 23
2016
Q3 		$1.22B Buy
26,570,988
+3,870,176
+17% +$202M 1.86% 22
2016
Q2 		$1.14B Buy
22,700,812
+13,385,352
+144% +$713M 1.74% 25
2016
Q1 		$498M Sell
9,315,460
-287,003
-3% -$16.8M 0.76% 42
2015
Q4 		$630M Buy
9,602,463
+80,062
+0.8% +$4.95M 0.94% 40
2015
Q3 		$538M Sell
9,522,401
-340,442
-3% -$22.1M 0.83% 42
2015
Q2 		$583M Sell
9,862,843
-327,061
-3% -$20.2M 0.79% 43
2015
Q1 		$635M Sell
10,189,904
-633,211
-6% -$36.8M 0.86% 43
2014
Q4 		$622M Buy
10,823,115
+452,762
+4% +$25.2M 0.83% 41
2014
Q3 		$557M Sell
10,370,353
-498,417
-5% -$26.4M 0.76% 43
2014
Q2 		$570M Sell
10,868,770
-2,466,997
-18% -$126M 0.77% 45
2014
Q1 		$705M Buy
13,335,767
+1,192,204
+10% +$55.1M 1.01% 39
2013
Q4 		$487M Buy
12,143,563
+5,383,797
+80% +$212M 0.71% 45
2013
Q3 		$255M Buy
6,759,766
+35,800
+0.5% +$1.4M 0.41% 50
2013
Q2 		$264M Buy
+6,723,966
New +$262M 0.44% 51

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's TEVA Position: Q2 2019 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 2,942,539 shares — an estimated $46.1M sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in TEVA in Q2 2013 and held it in 24 quarters. The position peaked at $1.22B in Q3 2016. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • Barrow, Hanley, Mewhinney & Strauss reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Barrow, Hanley, Mewhinney & Strauss sold 2,942,539 Teva Pharmaceuticals shares in Q2 2019, an estimated $46.1M.
  • Barrow, Hanley, Mewhinney & Strauss first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 24 quarters.
  • Barrow, Hanley, Mewhinney & Strauss's Teva Pharmaceuticals position peaked at $1.22B in Q3 2016.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q2 2019, filed 13 Aug 2019.